APA

Dieras V., Pop S., Berger F., Dujaric M., Beuzeboc P., Escalup L., Bidard F. C., Cottu P. H., LE Tourneau C., Piperno-Neumann S., Laurence V., Robain M., Asselain B. & Pierga J. (20170411). First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. : Anticancer research.

Chicago

Dieras Veronique, Pop Simona, Berger Frederique, Dujaric Marie-Eglantine, Beuzeboc Philippe, Escalup Laurence, Bidard François Clement, Cottu Paul Henri, LE Tourneau Christophe, Piperno-Neumann Sophie, Laurence Valerie, Robain Mathieu, Asselain Bernard and Pierga Jean-Yves. 20170411. First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. : Anticancer research.

Harvard

Dieras V., Pop S., Berger F., Dujaric M., Beuzeboc P., Escalup L., Bidard F. C., Cottu P. H., LE Tourneau C., Piperno-Neumann S., Laurence V., Robain M., Asselain B. and Pierga J. (20170411). First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. : Anticancer research.

MLA

Dieras Veronique, Pop Simona, Berger Frederique, Dujaric Marie-Eglantine, Beuzeboc Philippe, Escalup Laurence, Bidard François Clement, Cottu Paul Henri, LE Tourneau Christophe, Piperno-Neumann Sophie, Laurence Valerie, Robain Mathieu, Asselain Bernard and Pierga Jean-Yves. First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. : Anticancer research. 20170411.